XML 69 R58.htm IDEA: XBRL DOCUMENT v3.22.2
Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 01, 2020
Mar. 31, 2022
Nov. 30, 2020
Jun. 30, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2019
Feb. 28, 2021
Jun. 30, 2020
Jan. 31, 2020
Jan. 01, 2020
Noncontrolling Interest [Line Items]                          
Payments to acquire additional interest in subsidiaries             $ 1,999,998 $ 0          
Share of net loss in Geneos       $ 0 $ 0   $ 2,165,213 $ 434,387          
Geneos Therapeutics, Inc.                          
Noncontrolling Interest [Line Items]                          
Noncontrolling interest, ownership percentage by parent   24.00% 36.00%           61.00% 35.00%     52.00%
Ownership percentage                     47.00%    
Geneos Therapeutics, Inc.                          
Noncontrolling Interest [Line Items]                          
Payments to acquire additional interest in subsidiaries     $ 1,400,000           $ 1,200,000        
Stock purchase agreement, commitment of additional investment                     $ 800,000 $ 800,000  
Gain on deconsolidation of investment $ 4,100,000                        
Remeasurement of Geneos Series A-1 preferred stock $ 2,400,000                        
Loss from equity method investment, recorded and allocated to investment           $ 1,500,000              
Share of net loss in Geneos           434,000              
Investment in equity method investments           0              
Geneos Therapeutics, Inc. | Series A One Preferred Stock                          
Noncontrolling Interest [Line Items]                          
Share of net loss in Geneos           819,000              
Geneos Therapeutics, Inc. | Common stock                          
Noncontrolling Interest [Line Items]                          
Investment in equity method investments           0              
Geneos Therapeutics, Inc. | Preferred stock                          
Noncontrolling Interest [Line Items]                          
Payments to acquire additional interest in subsidiaries   $ 2,000,000                      
Share of net loss in Geneos           4,200,000              
Investment in equity method investments           $ 0